We are analyzing https://link.springer.com/article/10.1186/s13045-020-00977-0.

Title:
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020) | Journal of Hematology & Oncology
Description:
Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding kinases from phosphorylating tyrosine residues of their substrates and then block the activation of downstream signaling pathways. Over the past 20 years, multiple robust and well-tolerated TKIs with single or multiple targets including EGFR, ALK, ROS1, HER2, NTRK, VEGFR, RET, MET, MEK, FGFR, PDGFR, and KIT have been developed, contributing to the realization of precision cancer medicine based on individual patient’s genetic alteration features. TKIs have dramatically improved patients’ survival and quality of life, and shifted treatment paradigm of various solid tumors. In this article, we summarized the developing history of TKIs for treatment of solid tumors, aiming to provide up-to-date evidence for clinical decision-making and insight for future studies.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

article, google, scholar, cancer, patients, pubmed, cas, oncol, phase, lung, advanced, treatment, nsclc, study, inhibitors, egfr, trial, clin, resistance, kinase, mutations, tyrosine, tkis, therapy, cell, trk, efficacy, metastatic, carcinoma, med, tumors, table, nonsmallcell, receptor, lancet, met, orr, combination, inhibitor, safety, growth, clinical, mutation, versus, suppl, crizotinib, engl, solid, survival, factor,

Topics {✒️}

anti-pd-1/pd-l1 antibodies pd-1/pd-l1 antibodies b-cell antigen receptor mitogen-activated protein kinase generation ros1/trk/alk inhibitor high-level met-amplified advanced b-cell-related hematological malignancies mesenchymal–epithelial transition factor ntrk fusion-positive tumours her2-positive breast cancer met-amplified egfr-mutant nsclc pathway—ras/raf/mek/erk her2-positive breast cancers wild-type tyrosine kinases ntrk fusion-positive cancers invasive breast cancer small-cell lung cancer small-cell lung carcinoma metastatic renal-cell carcinoma previously-treated advanced cholangiocarcinoma kinase-targeted cancer therapies advanced ros1 fusion-positive egfr-tyrosine kinase inhibitors advanced egfr mutation-positive egfr mutation-positive advanced advanced renal-cell carcinoma irreversible pan-erbb inhibitor trk fusion-positive cancers cis-c797s triple mutations alk-positive lung cancer egfr-mutant lung cancer ret fusion-positive nsclc reversible egfr/her2-tki prior anti-her2 treatment chronically sun-damaged skin generation irreversible egfr-tki article download pdf metastatic alk-positive nsclc egfr-sensiting-mutant nsclc potent anti-tumor weapons generation reversible egfr-tkis t790m mutation-positive nsclc multi-functional polypeptide involved augment anti-angiogenesis effect radioiodine-refractory thyroid cancer ret fusion-positive nsclcs fourth-generation egfr-tkis generation alk-tkis warrants fibroblast growth factor highly selective her2-tki

Questions {❓}

Capmatinib and gefitinib combination therapy: will EGFR-mutated MET-dysregulated NSCLC “capitulate”?
Minireview: were the IGF signaling inhibitors all bad?
Newer-generation EGFR inhibitors in lung cancer: how are they best used?
Tyrosine kinase inhibitors: multi-targeted or single-targeted?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
         description:Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding kinases from phosphorylating tyrosine residues of their substrates and then block the activation of downstream signaling pathways. Over the past 20 years, multiple robust and well-tolerated TKIs with single or multiple targets including EGFR, ALK, ROS1, HER2, NTRK, VEGFR, RET, MET, MEK, FGFR, PDGFR, and KIT have been developed, contributing to the realization of precision cancer medicine based on individual patient’s genetic alteration features. TKIs have dramatically improved patients’ survival and quality of life, and shifted treatment paradigm of various solid tumors. In this article, we summarized the developing history of TKIs for treatment of solid tumors, aiming to provide up-to-date evidence for clinical decision-making and insight for future studies.
         datePublished:2020-10-27T00:00:00Z
         dateModified:2020-10-27T00:00:00Z
         pageStart:1
         pageEnd:23
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s13045-020-00977-0
         keywords:
            Tyrosine kinase inhibitors
            Solid tumors
            Targeted therapy
            Oncology
            Hematology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13045-020-00977-0/MediaObjects/13045_2020_977_Fig1_HTML.png
         isPartOf:
            name:Journal of Hematology & Oncology
            issn:
               1756-8722
            volumeNumber:13
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Liling Huang
               affiliation:
                     name:Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs
                     address:
                        name:Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Shiyu Jiang
               affiliation:
                     name:Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs
                     address:
                        name:Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yuankai Shi
               url:http://orcid.org/0000-0002-8685-6744
               affiliation:
                     name:Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs
                     address:
                        name:Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
      description:Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding kinases from phosphorylating tyrosine residues of their substrates and then block the activation of downstream signaling pathways. Over the past 20 years, multiple robust and well-tolerated TKIs with single or multiple targets including EGFR, ALK, ROS1, HER2, NTRK, VEGFR, RET, MET, MEK, FGFR, PDGFR, and KIT have been developed, contributing to the realization of precision cancer medicine based on individual patient’s genetic alteration features. TKIs have dramatically improved patients’ survival and quality of life, and shifted treatment paradigm of various solid tumors. In this article, we summarized the developing history of TKIs for treatment of solid tumors, aiming to provide up-to-date evidence for clinical decision-making and insight for future studies.
      datePublished:2020-10-27T00:00:00Z
      dateModified:2020-10-27T00:00:00Z
      pageStart:1
      pageEnd:23
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s13045-020-00977-0
      keywords:
         Tyrosine kinase inhibitors
         Solid tumors
         Targeted therapy
         Oncology
         Hematology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13045-020-00977-0/MediaObjects/13045_2020_977_Fig1_HTML.png
      isPartOf:
         name:Journal of Hematology & Oncology
         issn:
            1756-8722
         volumeNumber:13
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Liling Huang
            affiliation:
                  name:Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs
                  address:
                     name:Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Shiyu Jiang
            affiliation:
                  name:Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs
                  address:
                     name:Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yuankai Shi
            url:http://orcid.org/0000-0002-8685-6744
            affiliation:
                  name:Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs
                  address:
                     name:Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Journal of Hematology & Oncology
      issn:
         1756-8722
      volumeNumber:13
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs
      address:
         name:Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing, China
         type:PostalAddress
      name:Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs
      address:
         name:Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing, China
         type:PostalAddress
      name:Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs
      address:
         name:Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Liling Huang
      affiliation:
            name:Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs
            address:
               name:Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing, China
               type:PostalAddress
            type:Organization
      name:Shiyu Jiang
      affiliation:
            name:Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs
            address:
               name:Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing, China
               type:PostalAddress
            type:Organization
      name:Yuankai Shi
      url:http://orcid.org/0000-0002-8685-6744
      affiliation:
            name:Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs
            address:
               name:Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing, China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing, China
      name:Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing, China
      name:Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, Beijing, China

External Links {🔗}(626)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.84s.

LINK . SPRINGER . COM {}